Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 17/20 | 0.64 |
| ▸ | LCK | P06239 | 8/20 | 0.64 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | JAK3 | P52333 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | LYN | P07948 | 1/20 | 0.64 |
| ▸ | BTK | Q06187 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564171 | 0.80 | TNK2 (0.73) | TNK2LCKKDRJAK3ABL1 | |
| SCHEMBL13461961 | 0.80 | TNK2 (0.73) | TNK2LCKKDRJAK3ABL1 | |
| SCHEMBL2966695 | 0.79 | TNK2 (0.84) | TNK2LCKKDRJAK3ABL1 | |
| SCHEMBL3562484 | 0.79 | TNK2 (1.00) | TNK2LCKKDRJAK3ABL1 | |
| SCHEMBL2967661 | 0.79 | TNK2 (1.00) | TNK2LCKKDRJAK3ABL1 | |
| SCHEMBL2965872 | 0.79 | TNK2 (1.00) | TNK2LCKKDRJAK3ABL1 | |
| SCHEMBL2974800 | 0.79 | TNK2 (1.00) | TNK2LCKKDRJAK3ABL1 | |
| SCHEMBL3566479 | 0.78 | KDM4E (0.53) | TNK2LCKKDRJAK3KDM4E | |
| SCHEMBL3572103 | 0.78 | KDM4E (0.52) | TNK2LCKKDRJAK3KDM4E | |
| SCHEMBL3563328 | 0.78 | AURKA (0.51) | TNK2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | claimed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | claimed |
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1791845-A2 | FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS | AMGEN INC. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006130160-A2 | FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS | AMGEN INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | LCK, NFATC1, MINK1 | TNK2 22/4885LCK 1/4885KDR 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.